This phase I/II study is trying to determine the appropriate dosing of a targeted therapy (AZD4573) alone, and then evaluate how effective it is when combined with another targeted therapy (acalabrutinib), in people with advanced blood cancersA Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Haematological Malignancies

Summary

This is a non-randomised trial that has two modules, each with two parts. In Module 1 Part A, participants will receive ascending doses of AZD4573 (administered intravenously [via IV]) once weekly, in combination with oral, twice daily doses of acalabrutinib. Part A will have three different cohorts, each with different target dose levels of AZD4573. The primary objective of Part A is to determine the maximum tolerated dose for Part B. In Module 1 Part B, participants will receive AZD4573 at the dose level determined in Part A. Module 2 Part A has two phases. In Phase 1, participants will receive AZD4573 alone (administered via IV once weekly). In Phase 2, participants will receive AZD4573 (administered via IV once weekly) in combination with acalabrutinib (orally, twice daily). Module 2 Part B will be determined based on the data that emerges from Part A.